Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Crhistian-Mario Oblitas, Pablo Demelo-Rodríguez, Marina López-Rubio, Marta-Olimpia Lago-Rodríguez, Mercedes García-Gámiz, Angielys Zamora-Trillo, Luis-Antonio Alvarez-Sala Walther, Rita García-Martínez, Francisco Galeano-Valle
BACKGROUND: Soluble P-selectin (sP-selectin) has been proposed as a potential biomarker for venous thromboembolism (VTE) diagnosis with interesting results. However, its role in predicting early mortality in pulmonary embolism (PE) remains unexplored. METHODS: This observational, prospective, single-center study enrolled consecutive patients aged 18 or older with confirmed acute symptomatic PE and no prior anticoagulation. The study aims to assess the prognostic capacity of sP-selectin measured at the time of PE diagnosis for short-term mortality and major bleeding...
April 23, 2024: European Journal of Haematology
#2
REVIEW
Julie Wang, Prahlad Ho, Harshal Nandurkar, Hui Yin Lim
Thromboembolic diseases including arterial and venous thrombosis are common causes of morbidity and mortality globally. Thrombosis frequently recurs and can also complicate many inflammatory conditions through the process of 'thrombo-inflammation,' as evidenced during the COVID-19 pandemic. Current candidate biomarkers for thrombosis prediction, such as D-dimer, have poor predictive efficacy. This limits our capacity to tailor anticoagulation duration individually and may expose lower risk individuals to undue bleeding risk...
April 22, 2024: Journal of Thrombosis and Thrombolysis
#3
JOURNAL ARTICLE
Nathan E Brummel, Christopher G Hughes, J Brennan McNeil, Pratik P Pandharipande, Jennifer L Thompson, Onur M Orun, Rameela Raman, Lorraine B Ware, Gordon R Bernard, Fiona E Harrison, E Wesley Ely, Timothy D Girard
PURPOSE: The purpose of this study was to determine associations between markers of inflammation and endogenous anticoagulant activity with delirium and coma during critical illness. METHODS: In this prospective cohort study, we enrolled adults with respiratory failure and/or shock treated in medical or surgical intensive care units (ICUs) at 5 centers. Twice per day in the ICU, and daily thereafter, we assessed mental status using the Richmond Agitation Sedation Scale (RASS) and the Confusion Assessment Method-Intensive Care Unit (CAM-ICU)...
April 22, 2024: Intensive Care Medicine
#4
REVIEW
Purvi Pravinchandra Patel, Tanya Egodage
Acute kidney injury (AKI) is one of the most common organ dysfunctions impacting ICU (intensive care unit) patients. Early diagnosis using the various classification systems and interventions that can be aided by use of biomarkers are key in improving outcomes. Once the patient meets criteria of AKI, many patient specific factors determine the optimal timing for and mode of renal replacement therapy. There are several special considerations in surgical ICU patients with AKI including management of intracranial hypertension in those with cerebral edema, anticoagulation in high-risk bleeding patients, and use of contrast imaging...
2024: Trauma Surgery & Acute Care Open
#5
REVIEW
Lina Khider, Benjamin Planquette, David M Smadja, Olivier Sanchez, Carla Rial, Guillaume Goudot, Emmanuel Messas, Tristan Mirault, Nicolas Gendron
BACKGROUND: Post-thrombotic syndrome (PTS) is the main long-term complication of deep vein thrombosis (DVT). Several therapies are being evaluated to prevent or to treat PTS. Identifying the patients most likely to benefit from these therapies presents a significant challenge. OBJECTIVES: The objective of this review was to identify risk factors for PTS during the acute phase of DVT. ELIGIBILITY CRITERIA: We searched the PubMed and Cochrane databases for studies published between January 2000 and January 2021, including randomized clinical trials, meta-analyses, systematic reviews and observational studies...
April 12, 2024: Thrombosis Research
#6
JOURNAL ARTICLE
Emma Calluy, Charlotte Beaudart, Majed S Alokail, Nasser M Al-Daghri, Olivier Bruyère, Jean-Yves Reginster, Etienne Cavalier, Aurélie Ladang
OBJECTIVES: To evaluate some confounding factors that influence the concentrations of S100 calcium binding protein B (S100B), glial fibrillary acidic protein (GFAP), and ubiquitin carboxyl-terminal hydrolase L-1 (UCH-L1) in older individuals. Indeed, recent guidelines have proposed the combined use of S100B and the "GFAP-UCH-L1" mTBI test to rule out mild traumatic brain injuries (mTBI). As older adults are the most at risk of mTBI, it is particularly important to understand the confounding factors of those mTBI rule-out biomarkers in aging population...
April 22, 2024: Clinical Chemistry and Laboratory Medicine: CCLM
#7
JOURNAL ARTICLE
Caiting Yang, Jie Han, Hai Liu, Yuyu He, Zhenhua Zhang, Xiaochun Liu, Farooq Waqas, Lizhong Zhang, Huiping Duan, Jing He, Li Dong
Exosomes carry large cargo of proteins, lipids, and nucleic acids, serving as versatile biomarkers for disease diagnosis and vehicles for drug delivery. However, up to date, no well recognized standard procedures for exosome storage were available for clinical application. This study aimed to determine the optimal storage conditions and the anticoagulants for plasma-derived exosome isolation. Fresh whole blood samples were collected from healthy participants and preserved in four different anticoagulants including sodium citrate (SC1/4), sodium citrate (SC1/9), lithium heparin (LH), or Ethylenediamine tetraacetic acid (EDTA), respectively...
December 2024: Platelets
#8
JOURNAL ARTICLE
Hanna Heloterä, Leea Siintamo, Niko Kivinen, Nicholas Abrahamsson, Vesa Aaltonen, Kai Kaarniranta
PURPOSE: The aim of the study was to explore factors affecting the progression of neovascular age-related macular degeneration (nAMD) and identify predictive factors that can estimate the duration of intravitreal treatments. METHODS: This retrospective real-world study included 421 nAMD patients treated at the Kuopio University Hospital during years 2007-2021. The collected data included background demographics, treatment history, visual acuity and retinal biomarker analysis...
April 10, 2024: Acta Ophthalmologica
#9
REVIEW
Mechanisms of Cardiovascular Calcification and Experimental Models: Impact of Vitamin K Antagonists.
Chiara Siracusa, Annarita Carino, Nicole Carabetta, Marzia Manica, Jolanda Sabatino, Eleonora Cianflone, Isabella Leo, Antonio Strangio, Daniele Torella, Salvatore De Rosa
Cardiovascular calcification is a multifactorial and complex process involving an array of molecular mechanisms eventually leading to calcium deposition within the arterial walls. This process increases arterial stiffness, decreases elasticity, influences shear stress events and is related to an increased risk of morbidity and mortality associated with cardiovascular disease. In numerous in vivo and in vitro models, warfarin therapy has been shown to cause vascular calcification in the arterial wall. However, the exact mechanisms of calcification formation with warfarin remain largely unknown, although several molecular pathways have been identified...
February 29, 2024: Journal of Clinical Medicine
#10
JOURNAL ARTICLE
Dominik Linz, Jason G Andrade, Elena Arbelo, Giuseppe Boriani, Guenter Breithardt, A John Camm, Valeria Caso, Jens Cosedis Nielsen, Mirko De Melis, Tom De Potter, Wolfgang Dichtl, Søren Zoega Diederichsen, Dobromir Dobrev, Nicolas Doll, David Duncker, Elke Dworatzek, Lars Eckardt, Christoph Eisert, Larissa Fabritz, Michal Farkowski, David Filgueiras-Rama, Andreas Goette, Eduard Guasch, Guido Hack, Stéphane Hatem, Karl Georg Haeusler, Jeff S Healey, Hein Heidbuechel, Ziad Hijazi, Lucas H Hofmeister, Leif Hove-Madsen, Thomas Huebner, Stefan Kääb, Dipak Kotecha, Katarzyna Malaczynska-Rajpold, José Luis Merino, Andreas Metzner, Lluís Mont, Ghulam Andre Ng, Michael Oeff, Abdul Shokor Parwani, Helmut Puererfellner, Ursula Ravens, Michiel Rienstra, Prashanthan Sanders, Daniel Scherr, Renate Schnabel, Ulrich Schotten, Christian Sohns, Gerhard Steinbeck, Daniel Steven, Tobias Toennis, Stylianos Tzeis, Isabelle C van Gelder, Roderick H van Leerdam, Kevin Vernooy, Manish Wadhwa, Reza Wakili, Stephan Willems, Henning Witt, Stef Zeemering, Paulus Kirchhof
AIMS: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). METHODS AND RESULTS: Eighty-three international experts met in Münster for 2 days in September 2023...
March 30, 2024: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
#11
JOURNAL ARTICLE
Isabela Rodrigues Tavares, Roberto Augusto Caffaro, Maria Fernanda Portugal, Camilla Moreira Ribeiro, Viviane Santana da Silva, Emily Krupa, Srdjan Nikolovski, Karen Falcão de Britto, Ana Cláudia Gomes Pereira Petisco, Maria Cristina Miranda, Sandra Gomes de Souza Santos, Marcela da Silva Dourado, Paula Veloso Siqueira, Fakiha Siddiqui, Jawed Fareed, Eduardo Ramacciotti
Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), represents a substantial healthcare challenge. Provoked and unprovoked DVT cases carry distinct risks and treatment considerations. Recognizing the limitations of this classification, molecular markers may enhance diagnostic precision and guide anticoagulation therapy duration relying on patient history and risk factors. This preliminary, open-label, prospective cohort study was conducted including 15 patients (10 provoked DVT and 5 unprovoked DVT) and a control group of healthy plasmatic subjects...
2024: Clinical and Applied Thrombosis/hemostasis
#12
JOURNAL ARTICLE
Jia-Yu Zhang, Zou-Rong Ruan, Bo Jiang, Dan-Dan Yang, Jia-Ying Wang, Yin Hu, Yong-Rui Wang, Yan-Mei Wang, Yun-Fei Lin, Ling-Ling Wang, Hong-Gang Lou
The purpose of this study was to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of frunexian (formerly known as EP-7041 and HSK36273) injection, a small molecule inhibitor of activated coagulation factor XI (FXIa), in healthy Chinese adult volunteers. This study was a randomized, placebo- and positive-controlled, sequential, ascending-dose (0.3/0.6/1.0/1.5/2.25 mg/kg/h) study of 5-day continuous intravenous infusions of frunexian. Frunexian administration exhibited an acceptable safety profile with no bleeding events...
April 2024: Clinical and Translational Science
#13
JOURNAL ARTICLE
Impact of therapeutic plasma exchange on intact protein S, apolipoproteins, and thrombin generation.
Hanna H Pitkänen, Mikko Haapio, Mika Saarela, Marja-Riitta Taskinen, Herm-Jan Brinkman, Riitta Lassila
INTRODUCTION: Therapeutic plasma exchange (TPE), with solvent/detergent (S/D)-treated plasma as replacement fluid, is an extracorporeal blood purification technique with major impact on both coagulation and lipids. Our previous in vitro study showed that S/D-plasma enhances thrombin generation by lowering intact protein S (PS) levels. AIMS: To evaluate the impact of altered lipid balance on coagulation phenotype during heparin-anticoagulated TPE with S/D-plasma, and to investigate whether the lowered intact PS levels with concomitant procoagulant phenotype, are recapitulated in vivo...
March 27, 2024: Transfusion and Apheresis Science
#14
REVIEW
Hikmat Abdel-Razeq, Mohammed J Al-Jaghbeer
Cancer is a known risk factor for venous thromboembolism (VTE). The wider adoption of immunotherapy and anti-angiogenic drugs in recent years have increased this risk further. Central venous catheters (CVCs) are widely used access devices utilized to deliver infusion therapy, mostly in ambulatory settings. The endothelial injury associated with the use of these catheters adds to the risk of VTE to already high-risk patients. The introduction of direct oral anticoagulants (DOACs), with its proven efficacy and safety in multiple clinical indications, have renewed the attention to VTE prophylaxis in cancer patients with CVC...
March 14, 2024: Journal of Clinical Medicine
#15
REVIEW
Cristian Locci, Elena Chicconi, Roberto Antonucci
Bromelain is a complex natural mixture of sulfhydryl-containing proteolytic enzymes that can be extracted from the stem or fruit of the pineapple. This compound is considered a safe nutraceutical, has been used to treat various health problems, and is also popular as a health-promoting dietary supplement. There is continued interest in bromelain due to its remarkable therapeutic properties. The mechanism of action of bromelain appears to extend beyond its proteolytic activity as a digestive enzyme, encompassing a range of effects (mucolytic, anti-inflammatory, anticoagulant, and antiedematous effects)...
March 21, 2024: Children
#16
REVIEW
Wanqing Xie, Szuyao Hsu, Yuxuan Lin, Lv Xie, Xia Jin, Ziyu Zhu, Yunlu Guo, Caiyang Chen, Dan Huang, Johannes Boltze, Peiying Li
BACKGROUND: Patients with malignancies have an increased risk of suffering ischemic stroke via several mechanisms such as coagulation dysfunction and other malignancy-related effects as well as iatrogenic causes. Moreover, stroke can be the first sign of an occult malignancy, termed as malignancy-associated ischemic stroke (MAS). Therefore, timely diagnostic assessment and targeted management of this complex clinical situation are critical. FINDINGS: Patients with both stroke and malignancy have atypical ages, risk factors, and often exhibit malignancy-related symptoms and multiple lesions on neuroimaging...
March 2024: CNS Neuroscience & Therapeutics
#17
JOURNAL ARTICLE
Konstantinos I Gkarmiris, Johan Lindbäck, John H Alexander, Christopher B Granger, Peter Kastner, Renato D Lopes, André Ziegler, Jonas Oldgren, Agneta Siegbahn, Lars Wallentin, Ziad Hijazi
BACKGROUND: BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve prognostication of cardiovascular events in patients with AF. METHODS AND RESULTS: BMP10 was measured using a prototype Elecsys immunoassay in plasma samples collected at randomization and after 2 months in patients with AF randomized to apixaban or warfarin in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial (n=2878)...
March 26, 2024: Journal of the American Heart Association
#18
MULTICENTER STUDY
Daisuke Kasugai, Taku Tanaka, Takako Suzuki, Yoshinori Ito, Kazuki Nishida, Masayuki Ozaki, Takeo Kutsuna, Toshiki Yokoyama, Hitoshi Kaneko, Ryo Ogata, Ryohei Matsui, Takahiro Goshima, Hiroshi Hamada, Azusa Ishii, Yusuke Kodama, Naruhiro Jingushi, Ken Ishikura, Ryo Kamidani, Masashi Tada, Hideshi Okada, Takanori Yamamoto, Yukari Goto
BACKGROUND: Coronavirus disease 2019 (COVID-19) features a hypercoagulable state, but therapeutic anticoagulation effectiveness varies with disease severity. We aimed to evaluate the dynamics of the coagulation profile and its association with COVID-19 severity, outcomes, and biomarker trajectories. METHODS: This multicenter, prospective, observational study included patients with COVID-19 requiring respiratory support. Rotational thromboelastometry findings were evaluated for coagulation and fibrinolysis status...
2024: Frontiers in Immunology
#19
JOURNAL ARTICLE
Yao Yao, Yanli Li, Qinchun Jin, Xiaoye Li, Xiaochun Zhang, Qianzhou Lv
Insufficient data exist regarding the investigation of the impact of novel oral anticoagulants (NOACs) on coagulation activation biomarkers in the context of left atrial appendage closure (LAAC) and device-related thrombosis (DRT). The study was designed to investigate the changes and presence of coagulation activation biomarkers between different antithrombotic strategies following LAAC. A total of 120 nonvalvular atrial fibrillation patients intolerant of long-term anticoagulants, who underwent successful WATCHMAN closure implantation, were enrolled (rivaroxaban, n = 82; dabigatran, n = 38)...
2024: Cardiovascular Therapeutics
#20
JOURNAL ARTICLE
Sara Reda, Nadine Schwarz, Jens Müller, Hannah L McRae, Johannes Oldenburg, Bernd Pötzsch, Heiko Rühl
BACKGROUND: Recently, we have shown alterations in the anticoagulant response to recombinant activated factor VII (rFVIIa)-induced coagulation activation in patients with thrombophilia. OBJECTIVES: This study aimed to extend this in vivo model to fibrinolysis biomarkers. METHODS: This interventional in vivo study included 56 patients with thrombophilia and previous venous thromboembolism (VTE+), 38 without VTE (VTE-), and 35 healthy controls...
February 2024: Research and Practice in Thrombosis and Haemostasis
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
